AllSci News
AstraZeneca’s Baxfendy becomes first aldosterone synthase inhibitor approved for hypertension in US
AstraZeneca (LSE/STO/NYSE: AZN) has received US FDA approval for Baxfendy (baxdrostat), making it the first aldosterone synthase inhibitor cleared for the treatment…
Genentech's Tecentriq gets FDA nod as adjuvant for muscle-invasive bladder cancer treatment
Genentech has secured an atezolizumab bladder cancer FDA approval for the adjuvant treatment of muscle-invasive bladder cancer, with the US FDA clearing...
Regeneron and Parabilis strike USD 2.325b deal for antibody-Helicon conjugate therapeutics
Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a research collaboration with private Cambridge, Massachusetts-based Parabilis Medicines to discover...
FDA approves AstraZeneca, Daiichi’s Enhertu for two earlier settings for HER2 breast cancer
AstraZeneca (LSE/STO/NYSE: AZN) and Daiichi Sankyo have received US FDA approval for Enhertu (trastuzumab deruxtecan) in two new indications. These cover HER2-positive…
Allogene terminates CAR-T deal with Overland Therapeutics, reclaims global rights
Allogene Therapeutics (Nasdaq: ALLO) has terminated its five-year regional licensing agreement with Overland Therapeutics, reclaiming full global rights to...
Amgen’s Tavneos faces liver injury scrutiny in Japan as Kissei halts new prescriptions
Amgen (Nasdaq: AMGN) is facing intensifying regulatory and safety pressure over Tavneos (avacopan) in Japan after partner Kissei Pharmaceutical (Tokyo: 4547) issued…
Candel's genetic therapy set for BLA in prostate cancer after showing 39% improvement in disease-free survival
Candel Therapeutics (Nasdaq: CADL) reported extended follow-up data from its Phase III trial of aglatimagene besadenovec in localized prostate cancer...
Regeneron's fianlimab and cemiplimab combination misses primary endpoint in Phase III melanoma trial
Regeneron Pharmaceuticals (Nasdaq: REGN) reported that its Phase III fianlimab LAG-3 melanoma trial did not meet its primary endpoint, with the combination...
Aardvark hit with FDA clinical hold on TAS2R drug's Phase III Prader-Willi trial
Aardvark Therapeutics (Nasdaq: AARD) announced that the US FDA has placed a full clinical hold on its investigational new drug application for ARD-101,...
Cabaletta Bio's CD19 CAR-Tshows early promise in Phase I/II trial for pemphigus vulgaris
Cabaletta Bio (Nasdaq: CABA) reported early clinical data for rese-cel (resecabtagene autoleucel) administered without preconditioning in pemphigus...
University of Pittsburgh receives USD 2.16m NIAID grant for phage therapy center targeting multidrug-resistant bacteria
The University of Pittsburgh has received a USD 2.16 million NIAID P01 program grant to establish the Pitt Center for Accelerating Phage Therapy (P-CAPT), a...
Quiver Bioscience secures USD 1.99m NIH grant for Nav1.7-targeting antisense oligonucleotide program
Quiver Bioscience, a Cambridge, Massachusetts-based biotech company, has received a USD 1.99 million NIH UG3 award from the National Institute of...
University of Washington backed with USD 1.2m grant to explore impact of diabetes on CVD in the young
The University of Washington has received a USD 1.2 million NHLBI R35 award to investigate how diabetes accelerates cardiovascular disease in youth, with...
Weill Cornell Medicine receives USD 3.8m NIAID grant for HIV-1 vaccine research
Weill Cornell Medicine has received a USD 3.8 million NIAID P01 program project grant to advance germline-targeting HIV-1 vaccine immunogen research, with...
University of Massachusetts Medical School Worcester receives USD 1.675m NIH grant for AAV gene therapy safety research
A safety question at the core of AAV gene therapy is drawing new federal attention, as the University of Massachusetts Medical School Worcester has received...
The AllSci Brief
Free, systematic R&D and deal news. Daily.